Scipher picks up Chemomab’s liver disease drug, Nasdaq listing in all-stock merger

FDA-approved drug may finally help immunotherapy defeat rare liver cancer

NIMBLE-CRC: NeoImmunoModulation Before Leveraging Excision in Colorectal Rectal Cancer

STAT+: Roche drug sets new standard for KRAS-driven lung cancer

Pexidartinib Offers Hope for a Rare Tumor—But Its Risks Matter as You Age

Deep phenotyping of skin tissue remodeling in patients with systemic sclerosis treated with CD19-CAR T cells

Cancer therapy spinout Myricx Bio agrees to US$1.5B acquisition by Novartis

Myricx Bio, a cancer therapy spinout from the Francis Crick Institute and Imperial College London, has agreed to be acquired by Novartis in